BAFFR CAR T cells for relapsed neuromyelitis optica
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a new treatment using your own immune cells, modified to target a protein on B cells, for people with neuromyelitis optica spectrum disorder (NMOSD) that has not responded to standard treatments. It aims to reduce relapses and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with AQP4 antibody-positive NMOSD.
- You have tried at least one immunosuppressant for over a year but your symptoms are still not well controlled.
- You have had at least two relapses in the last year, or three in the last two years, with at least one in the last year.
- You are willing to use reliable contraception for one year after the infusion.
- You must not have had B cell depletion therapy in the last 6 months, and must not have active infections like hepatitis B, C, HIV, CMV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new treatment using your own immune cells (called BAFF-R CAR T cells) for people with severe nerve and immune diseases that have not improved with standard medicines. These cells are designed to target and destroy certain immune cells that may be causing your illness.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new CAR-T cell treatment that targets a protein called BAFFR on cancer cells. It is for people with B-cell lymphoma that has come back or not responded to previous treatments.
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
Hear when a new Neuromyelitis Optica Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.